Novartis Canada is pleased to announce that Fabhalta® (iptacopan capsules) is now available across Canada for adult patients ...

Also in the spotlight is LNP023, an orally-active Factor B inhibitor in development for diseases associated with the complement pathway, including paroxysmal nocturnal hemoglobinuria (PNH).

A Randomized, Multicenter, Active-Comparator Controlled, Open-Label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily LNP023 in Adult Patients With PNH and Residual Anemia, Despite ...